Video
Dr. Wilky on Ongoing Trial of Pembrolizumab and Axitinib in Sarcoma
Author(s):
In Partnership With:
Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.
Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the status of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.
This is a clinical trial that is currently in progress, Wilky explains. Therefore, there are not yet any published findings. However, she adds, there are 13 of the 30 planned patients enrolled, several of which have alveolar soft part sarcoma, but also other histologies in soft tissue sarcoma.
She explains that there have not been any prohibitive, severe toxicities from the combination. It is hopeful that preliminary results will be ready to be presented at the 2017 ASCO Annual Meeting.
